Author:
Alvar Jorge,Alves Fabiana,Bucheton Bruno,Burrows Louise,Büscher Philippe,Carrillo Eugenia,Felger Ingrid,Hübner Marc P.,Moreno Javier,Pinazo Maria-Jesus,Ribeiro Isabela,Sosa-Estani Sergio,Specht Sabine,Tarral Antoine,Wourgaft Nathalie Strub,Bilbe Graeme
Abstract
AbstractProgress has been made in the control or elimination of tropical diseases, with a significant reduction of incidence. However, there is a risk of re-emergence if the factors fueling transmission are not dealt with. Although it is essential to understand these underlying factors for each disease, asymptomatic carriers are a common element that may promote resurgence; their impact in terms of proportion in the population and role in transmission needs to be determined. In this paper, we review the current evidence on whether or not to treat asymptomatic carriers given the relevance of their role in the transmission of a specific disease, the efficacy and toxicity of existing drugs, the Public Health interest, and the benefit at an individual level, for example, in Chagas disease, to prevent irreversible organ damage. In the absence of other control tools such as vaccines, there is a need for safer drugs with good risk/benefit profiles in order to change the paradigm so that it addresses the complete infectious process beyond manifest disease to include treatment of non-symptomatic infected persons.
Funder
Drugs for Neglected Diseases initiative
Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献